Eli Lilly & Co. approved a program to buy back as much as $15 billion of its own shares amid rapid growth fueled in part by ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
Roche is developing the tests in partnership with Indianapolis-based Eli Lilly and Co. Earlier this year, the U.S. Food and ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 524.46% and ...
CBS News reports that workplace violence at Allina Health's Abbott Northwestern Hospital has led to more than $83,000 in fines over the past year. Other news from the health industry is on the demand ...
Joe Breen, 38, is one of thousands of people whose experiences with GLP-1s such as Ozempic and Wegovy have radically changed their relationship with alcohol. Here, we unpack the latest research on GLP ...
The FDA put both peptides on its shortage list in 2022. Semaglutide is still on that list, while the FDA lifted its shortage ...
Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.
It didn’t take long for the shine to come off one of biotech’s recent IPO success stories, with BioAge Labs scrapping a phase ...
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
Lilly announces a $3B expansion in Wisconsin to boost production of weight loss drugs and strengthen its position in the ...